Yasunobu Abe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yasunobu Abe has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Akiko Takamatsu
Division of Hematology, National Kyushu Cancer Center, National Hospital Organization , Fukuoka , Japan
1 shared publication- Eiichi Ohtsuka
Department of Hematology, Oita Prefectural Hospital, Oita, Japan
1 shared publication - Goichi Yoshimoto
Department of Hematology, Kyushu Medical Center, Fukuoka, Japan
1 shared publication Ilseung Choi
Division of Hematology, National Kyushu Cancer Center, National Hospital Organization, Fukuoka, Japan
1 shared publication- Koichi Akashi
Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine, Fukuoka, Japan
1 shared publication - Koji Nagafuji
Division of Hematology and Oncology, Department of Medicine Kurume University Hospital Kurume Japan
1 shared publication
Latest Publications
- 6 November 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 55 (7) , 1663-1664
Successful treatment with allogeneic hematopoietic stem cell transplant in a mature B-cell leukemia withMYCandBCL2translocation
B-cell lymphoma with concurrent 18q21/BCL2 and 8q24/MYC translocations is known as double-hit lymphoma [1]. The BCL2 gene usually translocates to the immunoglobulin heavy chain (IGH) gene as t(14;1...
- 6 November 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 55 (7) , 1663-1664
Successful treatment with allogeneic hematopoietic stem cell transplant in a mature B-cell leukemia withMYCandBCL2translocation
B-cell lymphoma with concurrent 18q21/BCL2 and 8q24/MYC translocations is known as double-hit lymphoma [1]. The BCL2 gene usually translocates to the immunoglobulin heavy chain (IGH) gene as t(14;1...
- Open Access
- 6 February 2013
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 6 (1) , 14
Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
Allogeneic hematopoietic stem cell transplantation (HSCT) for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is much more intensive than multi-agent combined chemotherapy, although allogeneic HSCT is associated with increased morbidity and mortality when compared with such chemotherapy. Minimal residual disease (MRD) status has been proven to be a strong prognostic factor for adult patients with Ph-negative ALL.
- 6 February 2013
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 6 (1) , 14
Open AccessMonitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
Allogeneic hematopoietic stem cell transplantation (HSCT) for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is much more intensive than multi-agent combined chemotherapy, although allogeneic HSCT is associated with increased morbidity and mortality when compared with such chemotherapy. Minimal residual disease (MRD) status has been proven to be a strong prognostic factor for adult patients with Ph-negative ALL.